APA

Focan C., Kreutz F., Graas M., Longrée L., Focan-Henrard D., Demolin G. & Moeneclaey N. (20131211). Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report of the BE-1603 study. : Pathologie-biologie.

Chicago

Focan C, Kreutz F, Graas M-P, Longrée L, Focan-Henrard D, Demolin G and Moeneclaey N. 20131211. Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report of the BE-1603 study. : Pathologie-biologie.

Harvard

Focan C., Kreutz F., Graas M., Longrée L., Focan-Henrard D., Demolin G. and Moeneclaey N. (20131211). Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report of the BE-1603 study. : Pathologie-biologie.

MLA

Focan C, Kreutz F, Graas M-P, Longrée L, Focan-Henrard D, Demolin G and Moeneclaey N. Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report of the BE-1603 study. : Pathologie-biologie. 20131211.